bims-ovdlit Biomed News
on Ovarian cancer: early diagnosis, liquid biopsy and therapy
Issue of 2022‒12‒04
six papers selected by
Lara Paracchini
Humanitas Research

  1. Cancer Discov. 2022 Dec 02. OF1
      Methylation-based approach was best performing for a cfDNA-based multicancer early detection test.
  2. Nat Genet. 2022 Dec 01.
      Fewer than half of all patients with advanced-stage high-grade serous ovarian cancers (HGSCs) survive more than five years after diagnosis, but those who have an exceptionally long survival could provide insights into tumor biology and therapeutic approaches. We analyzed 60 patients with advanced-stage HGSC who survived more than 10 years after diagnosis using whole-genome sequencing, transcriptome and methylome profiling of their primary tumor samples, comparing this data to 66 short- or moderate-term survivors. Tumors of long-term survivors were more likely to have multiple alterations in genes associated with DNA repair and more frequent somatic variants resulting in an increased predicted neoantigen load. Patients clustered into survival groups based on genomic and immune cell signatures, including three subsets of patients with BRCA1 alterations with distinctly different outcomes. Specific combinations of germline and somatic gene alterations, tumor cell phenotypes and differential immune responses appear to contribute to long-term survival in HGSC.
  3. JNCI Cancer Spectr. 2022 Dec 01. pii: pkac084. [Epub ahead of print]
  4. Science. 2022 Dec 02. 378(6623): 948-949
      Active DNA demethylation maintains enhancer activity in nonproliferating cells but can damage DNA.